In this retrospective analysis, we evaluated brentuximab vedotin as monotherapy or in combination therapy in patients with cutaneous CD30‐positive peripheral T cell lymphoma (n  =  9). Here, TNFRSF8 is linked to peripheral T-cell lymphoma, not otherwise specified.